Bioceres ( BIOX ) presented 1Q26 results (3Q25 calendar), showing continued challenges in the topline across all markets, with a somewhat offsetting better performance in gross margins, and especially big cuts in OpEx leading to better profitability.Long-only investment, evaluating companies from an operational, buy-and-hold perspective.Quipus Capital does not focus on market-driven dynamics and future price action. Instead, our articles focus on operational aspects, understanding the long-term earnings pow ...